励晶(00575.HK)逆市劲弹82%价量齐创新高 商业夥伴早泄药获欧盟批准转为非处方药
励晶太平洋(00575.HK)公布商业夥伴Recordati治疗早泄药获欧盟批准转为非处方药,此举旨在大幅提升销量及继而增加支付给集团之专利权使用费。该股今天逆市突破52周高位0.191元,曾飙升1.1倍至0.24元,创逾13个月高,现造0.204元,急弹82%,一向薄弱成交激增至5.47亿股,为多年来罕见,涉资1.07亿元。
励晶太平洋公布,商业夥伴Recordati S.p.A已於8月27日获欧盟批准,治疗早泄药Fortacin之营销授权由处方药转为非处方药,此举旨在大幅提升销量及继而增加支付给集团之专利权使用费。Recordati、PSNW 及集团正在探讨扩大生产规模之各种方案,以满足估计对非处方药之需求,目标是每批量订单生产约5万单位,并减少供应链短缺及不可靠之风险。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.